SLC35A1 and neoplasm: By using sialidase treatment, the sialyltransferase inhibitor P3-FAX, or SLC35A1 KO tumor cells to remove or prevent sialic acid expression on the surface of tumor cells, we demonstrate a notable enhancement in neutrophil-mediated killing efficacy.